drug deliveryCell therapies: breaking barriers in solid tumoursIt’s been nearly a decade since the first CAR-T cancer cell therapy was approved by the FDA, offering a powerful and durable therapy against tumours. But when it comes to fighting solid tumours, … more ➔
licensingBoehringer backs Envisagenics in $1B RNA splicing dealBoehringer Ingelheim has partnered with New York-based Envisagenics to hunt for new targets in hard-to-treat solid tumors, opening up more than $1 billion (€873 million) in potential payments. more ➔
AIBig Picture Bio launches with £2.2M to design cancer combinationsLondon-based Big Picture Bio has launched with £2.2 million (€2.6 million) in funding to build an AI platform that designs drug combinations for cancer, starting largely with medicines that are already … more ➔
AlzheimerRemynd receives €3.5M for Alzheimer’s trialBelgian biotech Remynd has secured a €3.5 million investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to move its septin-modulating drug REM392 into patients with mild-to-moderate Alzheimer’s … more ➔
licensingNovartis licenses BoomRay radioligand asset for $900MNovartis has licensed an undisclosed preclinical radioligand therapy from China’s BoomRay Pharmaceuticals in a deal worth up to $900 million (€786 million), adding another asset to one of the pharma … more ➔
retinitis pigmentosaBeacon’s XLRP gene therapy meets pivotal U.S. endpointBeacon Therapeutics’ gene therapy laru-zova met its U.S. pivotal endpoint in X-linked retinitis pigmentosa, while results on the trial’s separately designated European primary efficacy measure were less … more ➔
M&ATelix to acquire ITM for $1.65B in radiopharma pushAustralian radiopharma company Telix Pharmaceuticals has agreed to acquire Munich-based ITM Isotope Technologies for an initial $1.65 billion (€1.44 billion), combining Telix’s commercial radiopharma … more ➔
fundraisingMatisse raises €14M for Phase 2 sepsis trialDutch biotech Matisse Pharmaceuticals has raised €14 million in a Series A financing to advance isupartob sodium through Phase 2 development in sepsis. more ➔
NovartisALSNovartis drops TREM2 antibody in ALS after Phase 2 missNovartis has stopped developing its TREM2 antibody VHB937 (lifonebart) in amyotrophic lateral sclerosis (ALS) after the 251-patient Phase 2 ASTRALS trial missed its primary and secondary endpoints, and … more ➔
NeurologyNovartis pays $125M for Sironax brain delivery platformNovartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an option it secured from the U.S.-Chinese biotech in July 2025. Sironax will … more ➔
Novartis
